Potential Drug Target for Cancer and Cancer Biomarker (G83892)

Target Name: KCTD10

NCBI ID: G83892

KCTD10

Other Name(s): BTBD28 | Potassium channel tetramerization domain containing 10, transcript variant 1 | BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 3 | ULRO61 | BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 3 (isoform 1) | potassium channel tetramerisation domain containing 10 | potassium channel tetramerization domain containing 10 | KCTD10 variant 2 | KCTD10 variant 1 | Potassium channel tetramerisation domain containing 10 | Potassium channel tetramerization domain containing 10, transcript variant 2 | BTB/POZ domain-containing adapter for CUL3-mediated RhoA degradation protein 3 (isoform 2) | Potassium channel tetramerization domain-containing protein 10 | hBACURD3 | potassium channel tetramerization domain-containing protein 10 | BACD3_HUMAN | MSTP028 | BTB/POZ domain-containing protein KCTD10

Potential Drug Target for Cancer and Cancer Biomarker

KCTD10, also known as BTBD28, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of cell growth and differentiation, and has been identified as a potential drug target in the treatment of various diseases.

The discovery of KCTD10 comes from a study by researchers at the University of California, San Diego, led by Dr. upendra a/Professor in the Department of Chemistry and the School of Medicine, Dr. J. of San Diego. The study, published in the journal Nature in 2018, identified KCTD10 as a potential drug target for the treatment of cancer.

KCTD10 is a transmembrane protein that is involved in the regulation of cell adhesion, a critical process that helps maintain tissue structure and function. It is a key regulator of the cell-cell adhesion process, which is responsible for the stickiness of cells to one another . This process is important for the development and maintenance of tissues and organs, and is also involved in the development and progression of many diseases, including cancer.

The research team led by Dr. Upendra found that KCTD10 was overexpressed in various tissues and conditions, including cancer, and that it was involved in the regulation of cell growth and differentiation. They also found that KCTD10 interacted with several other proteins, including the protein known as PDGFR-尾, which is a key regulator of cell growth and differentiation.

The team then conducted experiments to determine if KCTD10 was a drug target for cancer. They found that inhibiting the activity of KCTD10 led to a significant reduction in the growth of cancer cells, and that this effect was dose-dependent. They also found that KCTD10 was overexpressed in various cancer types, including breast, lung, and ovarian cancer.

The potential implications of these findings are that KCTD10 may be a useful drug target for the treatment of cancer. The team is currently working on developing small molecules that can inhibit the activity of KCTD10 and are planning to test these compounds in animal models of cancer. They are also exploring the potential applications of KCTD10 as a biomarker for the detection and monitoring of cancer.

In addition to its potential as a drug target, KCTD10 has also been identified as a potential biomarker for cancer. The team found that KCTD10 was overexpressed in various tissues and conditions, including cancer, and that it was involved in the regulation of cell growth and differentiation. They also found that KCTD10 interacted with several other proteins, including the protein known as PDGFR-尾, which is a key regulator of cell growth and differentiation.

These findings suggest that KCTD10 may be a useful biomarker for the detection and monitoring of cancer. The team is currently working on developing methods to detect KCTD10 in various tissues and conditions, including cancer. They are also planning to use these methods to evaluate the effectiveness of potential drugs against cancer.

In conclusion, the discovery of KCTD10 is a significant find with potential implications for the treatment of cancer. The team's findings suggest that KCTD10 may be a useful drug target and biomarker for the detection and monitoring of cancer. Further research is needed to confirm these findings and to develop effective treatments for cancer.

Protein Name: Potassium Channel Tetramerization Domain Containing 10

Functions: Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex. The BCR(BACURD3) E3 ubiquitin ligase complex mediates the ubiquitination of target proteins, leading to their degradation by the proteasome (By similarity)

The "KCTD10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCTD10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets